NasdaqCM:CORTPharmaceuticals
How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ (CORT) Risk-Reward Profile
In February 2026, Corcept Therapeutics reported that full-year 2025 net income fell to US$99.65 million from US$141.21 million a year earlier, while guiding 2026 net revenue to a range of US$900 million to US$1,000 million.
At the same time, the company faced mounting legal and regulatory pressure, with multiple securities class actions filed after the FDA issued a Complete Response Letter requiring more evidence for its relacorilant New Drug Application in Cushing’s syndrome.
We’ll now...